Antimicrobial Activity of Milk Whey in Different Mammals.

Antimicrobial activity of milk whey in different mammals against Candida albicans yeast cells was studied by a spectrophotometric method. The activity increased in the order goat→horse→camel→cow→human→mouse. The level of whey activity in mice was higher by 3 and 10 times than in humans and goats, respectively. Similar changes were noted for activity of the whey fraction <100 kDa containing a complex of antimicrobial polypeptides, and there was a direct correlation between these two parameters (r=0.881; p<0.05). The total activity of whey had a high degree of correlation with the content of serum albumin (r=0.992); in mice, the level of serum albumin in the milk whey was close to that in blood serum. Interspecific differences between the activity of whey in mammals may be associated with qualitative and quantitative variability of the antimicrobial polypeptide composition, as well as their synergistic or antagonistic interaction with each other.

[Analysis of the effectiveness and long-term results of formation of adaptive immunity in the use of various medications and vaccination schemes against pneumococcal infection in patients with chronic obstructive pulmonary disease]. / Analiz otdalennykh rezul'tatov éffektivnosti i formirovaniia adaptivnogo immuniteta pri primenenii raznykh preparatov i skhem vaktsinatsii protiv pnevmokokkovoi infektsii u bol'nykh s khronicheskoi obstruktivnoi bolezn'iu legkikh.

AIM: To assess the long-term clinical results of vaccination with pneumococcal polysaccharide and conjugated polysaccharide vaccines in the separate and sequential use, by determining the optimal vaccination schedule in adult patients with chronic obstructive pulmonary disease (COPD) and to investigate adaptive immunity levels. SUBJECTS AND METHODS: The clinical effects of vaccination were evaluated in patients with COPD within 1 and 4 years after immunization against pneumococcal infection using various schemes, as well as the time course of changes in adaptive immunity indicators was examined. RESULTS: Four years after vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13)/23-valent pneumococcal polysaccharide vaccine (PPV23) group showed a decline in the number of patients with COPD exacerbations by 50% (p<0.001) and reductions in the number of antimicrobial chemotherapy cycles by 47.8% (p<0.001) and in that of hospitalizations by 87.5% (p<0.001). At 1 year after vaccination versus at baseline, the COPD patients vaccinated against pneumococcal disease, regardless of the drug and schedule of vaccination, displayed elevated levels of IgG antibodies to the mixture of capsular polysaccharides included in PPV23 and PCV13. CONCLUSION: It has been indicated that a complex of basic therapy for patients with COPD should include initial vaccination with PCV13, followed by administration of a booster dose of PPV23.

[SYNTHETIC CONJUGATED ANALOGUES OF CAPSULE POLYSACCHARIDES OF PNEUMOCOCCUS - AN INSTRUMENT FOR DETECTION OF POST-VACCINATION ANTIBODIES].

AIM: Evaluation ofthe ability of capsule polysaccharides (CP) of Streptococcus pneumoniae serotype 3 and 14 and their synthetic structure analogues, conjugated with bovine serum albumin (BSA), to detect antibodies in post-vaccination sera of mice. Materials andmethods. Oligosaccharides correspond- ing to one, one and a half and two repeating links of serotype 3 and 14 S. pneumoniae CP were synthe- sized, their conjugates with BSA were produced by squarate method as well. Ligand content-per BSA molecule was controlled by MALDI-TOF spectrometry. Immune sera were obtained after 2 intraperi- toneal administrations to mice of glucoconjugates adsorbed on aluminum hydroxide or 13-valent pneumococcal conjugated vaccine. Determination of levels of post-vaccination class G antibodies and their sub-isotypes was carried out in EIA. RESULTS: Immunization of mice with neoglucoconjugates resulted in formation of predominantly IgGl recognizing serotype 3 and 14 S. pneumoniae C. IgG1 in mice immunized with a 13-valent conjugated vaccine recognized serotype 3 S. pneumoniae CP, but detected serotype 14 S. pneumoniae CP weakly. All the conjugated synthetic oligosaccharides were characterized by a high ability to bind antibodies in blood of mice immunized with the polysaccharide conjugated vaccine. BSA-tetrasaccharide of serotype 3 S. pneumoniae and BSA-tetrasaccharide of serotype 14 S.pneumoniae were characterized by the highest ability to detect IgG1 against C. CONCLUSION: Synthetic oligosaccharides, conjugated with BSA protein-carrier, may be used to develop diagnostic test-systems for determination of antibodies in post-vaccination sera.

[SPECIFIC IMMUNE RESPONSE TO CERTAIN CAPSULE POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE IN HEALTHY BLOOD DONORS AND INDIVIDUALS IMMUNIZED WITH PNEUMOCOCCAL VACCINES].

AIM: Evaluate humoral immune IgG response to 13 specific capsule polysaccharides in healthy blood donors and individuals immunized with pneumococcal vaccines. MATERIALS AND METHODS: A solid-phase EIA method was used with sorption on polystyrol of pneumococcal CPS isolated by us (1, 3, 4, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F, 23F). Blood sera of 140 healthy donors, 42 conscripts (young males) vaccinated with Pneumo-23 and 5 adults that are frequently ill with various bronchial-lung diseases for a long time and vaccinated with Prevenar-13 preparation were analyzed. IgG level was expressed in conventional units. RESULTS: The mean level of antibodies against pneumococcal CPS in donors was at the level of 70. c.u.; in conscripts during the prevaccination period--50 c.u.; in frequently ill for a long time--90 c.u. In 14 of 140 donors increased antibody levels against one or several CPS simultanously were observed. During post-vaccinal period in vaccinated with Pneumo-23 an increase of antibody levels against 12 - 13 CPS varying by specificity was observed only in 9 of 42 individuals; 1 individual did no have an increase of antibody levels against any of the 13 CPS; in 32 of 42--the antibody levels against 1 or several CPS did not increase. In 5 individuals vaccinated with Prevenar-13 a rise of antibody levels against 1 - 9 CPS, that are included in the vaccine, was not detected. CONCLUSION: Thus, clinical trials during registration of newly developed vaccines should, in our opinion, include evaluation of the initial levels of specific antibodies against each polysaccharide component of the vaccine in blood sera of all groups of volunteers. This would allow to evaluate the effectiveness of the vaccination.

[EPITOPIC SPECIFICITY OF A SYNTHETIC DISACCHARIDE, RECURRING LINK OF CAPSULE POLYSACCHARIDE CHAIN OF SEROTYPE 3 STREPTOCCUS PNEUMONIAE].

AIM: Study epitopic specificity of synthetic disaccharide, recurring link of serotype 3 S. pneumoniae, conjugated with bovine serum albumin (BSA). MATERIALS AND METHODS: Conjugate of the synthetic disaccharide with BSA was obtained by squarate method. Antigenic activity of the conjugate was studied in competitive EIA. Titers of IgG against capsule polysaccharide of serotype 3 S. pneumoniae were determined in EIA by using sera of mice immunized twice with disaccharide conjugate sorbed onto aluminum hydroxide. RESULTS: Disaccharide conjugate used as a well-covering antigen (4 µg/well) in EIA was characterized by a high degree of specificity and interacted only with IgG against serotype 3 S. pneumoniae in antimicrobial sera of animals without reacting with antibodies (ABs) against other pneumococcus serotypes (6B, 10A, 19A, 19F, 23F). Disaccharide conjugated with BSA was determined in competitive EIA to inhibit bonding of ABs to disaccharide by 78.8%, bacterial capsule polysaccharide by 56.9%, BSA did not inhibit the sera activity. The study of sera of mice immunized by serotype 3 S. pneumoniae disaccharide conjugate in EIA, where capsule polysaccharide was used as a plate-sorbed antigen, has established the presence of IgG against capsule polysaccharide at a titer of 1:1600. CONCLUSION: The disaccharide that is a single recurring link of serotype 3 S. pneumoniae contains a key epitope of capsule polysaccharide. The synthetic disaccharide could be used as a component of multivalent conjugated pneumococcal vaccines and for development of diagnostic test-systems.

[The level of antibodies to pneumococcal vaccine in children and adolescents with type 1 diabetes].

The trend in the formation of postvaccinal antibodies (Ab) to a mixture of S. pneumoniae polysaccharides (PS) was studied in 100 Pneumo 23-vaccinated children and adolescents with type 1 diabetic (T1D) (Group 1, n = 72) and its combination with the subunit vaccine Grippol (Group 2, n = 28). Following 1-1.5 months, the protective level of Ab l 40 conventional units (CU/ml) was revealed in 95.1 and 85.2% of Groups 1 and 2, respectively; and after 1 year, this was in 55.1 and 37%, respectively (p > 0.05). The level of formation of IgG Ab to a PS mixture did not depend on the age of patients, the duration of T1D, the presence of late diabetic complications. A relationship was found between the formation of postvaccinal Ab and their baseline level: in patients with very low (< 10 CU/ml) and low (10-20 CU/ml) levels of Ab after administration of pneumococcal vaccine, the level of IgG Ab to a S. pneumoniae PS mixture increased by 8.8-4.1 times in the early periods and exceeded the baseline levels by 4.8-2.8 times, respectively. The putative protective level of IgG AB to a S. pneumoniae PS mixture is proposed to be l 20 CU/ml.